Vicriviroc malate is a potent CCR5 antagonist with an IC50 of 0.91 nM, exhibiting broad-spectrum activity against genetically diverse HIV-1 isolates, including those with RTI, PRI, and MDR phenotypes; it is in Phase 3 clinical development. It inhibits MIP-1α-induced migration of Ba/F3 cells stably expressing recombinant human CCR5 (IC50 = 0.91 nM), suppresses RANTES-induced intracellular calcium release in U-87-CCR5 cells (IC50 = 16 nM), and inhibits GTPγS binding to RANTES-stimulated HTS-hCCR5 cell membranes (IC50 = 4.2 nM). Vicriviroc demonstrates potent antiviral activity against a panel of 30 R5-tropic HIV-1 isolates representing diverse genetic clades, with EC50 values ranging from 0.04 nM to 2.3 nM and EC90 values from 0.45 nM to 18 nM, showing 2- to 40-fold greater potency than SCH-C. It is also highly effective against the Clade G Russian isolate RU570 (EC90 = 16 nM), which is resistant to SCH-C (EC90 > 1 μM). Vicriviroc targets the early stage of the HIV-1 life cycle prior to reverse transcription and virion maturation, and shows no activity against viruses that utilize the CXCR4 coreceptor (R5/X4 or X4-tropic).